Physiologically‐Based Pharmacokinetic Modeling of the Drug–Drug Interaction of the UGT Substrate Ertugliflozin Following Co‐Administration with the UGT Inhibitor Mefenamic Acid...

Por Callegari, Ernesto, Lin, Jian, Tse, Susanna, Goosen, Theunis C., Sahasrabudhe, Vaishali
Publicado no CPT Pharmacometrics Syst Pharmacol (2020)

Pharmacokinetic Properties of Single and Multiple Doses of Ertugliflozin, a Selective Inhibitor of SGLT2, in Healthy Chinese Subjects

Por Li, Yinhua, Mu, Yuting, Shi, Haihong, Liang, Yali, Liu, Zeyuan, Matschke, Kyle, Hickman, Anne, Krishna, Rajesh, Sahasrabudhe, Vaishali
Publicado no Clin Pharmacol Drug Dev (2019)

A PK/PD study comparing twice-daily to once-daily dosing regimens of ertugliflozin in healthy subjects

Por Dawra, Vikas Kumar, Liang, Yali, Shi, Haihong, Bass, Almasa, Hickman, Anne, Terra, Steven G., Zhou, Susan, Cutler, David, Sahasrabudhe, Vaishali
Publicado no Int J Clin Pharmacol Ther (2019)

Bioequivalence of Ertugliflozin/Metformin Fixed‐Dose Combination Tablets and Coadministration of Respective Strengths of Individual Components

Por Dawra, Vikas Kumar, Liang, Yali, Wei, Hua, Pelletier, Kathleen, Shi, Haihong, Hickman, Anne, Bass, Almasa, Terra, Steven G., Zhou, Susan, Krishna, Rajesh, Sahasrabudhe, Vaishali
Publicado no Clin Pharmacol Drug Dev (2019)

Overview of the Clinical Pharmacology of Ertugliflozin, a Novel Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor

Por Fediuk, Daryl J., Nucci, Gianluca, Dawra, Vikas Kumar, Cutler, David L., Amin, Neeta B., Terra, Steven G., Boyd, Rebecca A., Krishna, Rajesh, Sahasrabudhe, Vaishali
Publicado no Clin Pharmacokinet (2020)

Assessment of the Drug Interaction Potential of Ertugliflozin With Sitagliptin, Metformin, Glimepiride, or Simvastatin in Healthy Subjects

Por Dawra, Vikas Kumar, Cutler, David L., Zhou, Susan, Krishna, Rajesh, Shi, Haihong, Liang, Yali, Alvey, Christine, Hickman, Anne, Saur, Didier, Terra, Steven G., Sahasrabudhe, Vaishali
Publicado no Clin Pharmacol Drug Dev (2018)

Effect of Food on the Pharmacokinetics of Ertugliflozin and Its Fixed‐Dose Combinations Ertugliflozin/Sitagliptin and Ertugliflozin/Metformin

Por Sahasrabudhe, Vaishali, Fediuk, Daryl J., Matschke, Kyle, Shi, Haihong, Liang, Yali, Hickman, Anne, Bass, Almasa, Terra, Steven G., Zhou, Susan, Krishna, Rajesh, Dawra, Vikas K.
Publicado no Clin Pharmacol Drug Dev (2018)

The use of plasma aldosterone and urinary sodium to potassium ratio as translatable quantitative biomarkers of mineralocorticoid receptor antagonism

Por Eudy, Rena J, Sahasrabudhe, Vaishali, Sweeney, Kevin, Tugnait, Meera, King-Ahmad, Amanda, Near, Kristen, Loria, Paula, Banker, Mary Ellen, Piotrowski, David W, Boustany-Kari, Carine M
Publicado em 2011

Bioequivalence of Ertugliflozin/Sitagliptin Fixed‐Dose Combination Tablets and Coadministration of Respective Strengths of Individual Components

Por Fediuk, Daryl J., Matschke, Kyle, Liang, Yali, Pelletier, Kathleen B., Wei, Hua, Shi, Haihong, Bass, Almasa, Hickman, Anne, Terra, Steven G., Zhou, Susan, Krishna, Rajesh, Sahasrabudhe, Vaishali
Publicado no Clin Pharmacol Drug Dev (2019)

Novel Application of the Two‐Period Microtracer Approach to Determine Absolute Oral Bioavailability and Fraction Absorbed of Ertugliflozin

Por Raje, Sangeeta, Callegari, Ernesto, Sahasrabudhe, Vaishali, Vaz, Alfin, Shi, Haihong, Fluhler, Eric, Woolf, Eric J., Schildknegt, Klaas, Matschke, Kyle, Alvey, Christine, Zhou, Susan, Papadopoulos, Dimitris, Fountaine, Robert, Saur, Didier, Terra, Steven G., Stevens, Lloyd, Gaunt, Daniel, Cutler, David L.
Publicado no Clin Transl Sci (2018)